enclosed
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.6 pts less than Nifty Smallcap 250 and 4.8 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Poly Medicure Ltd reported audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026. The Board recommended a dividend of Rs. 3.5 per equity share (70% payout) for FY 2025-26, subject to shareholder approval. Consolidated profit after tax grew marginally by approximately 4.6% to Rs. 33,557.77 lakhs from Rs. 32,072.95 lakhs in the previous year. During the year, the company completed two major acquisitions: Pendracare Group (acquired 80% economic rights for Rs. 14,825.77 lakhs cash outflow) and Medistream SA/Citeffe Group (acquired 100% for Rs. 18,510.08 lakhs cash outflow), both accounted for on a provisional basis. The company also received NCLT approval for acquiring Himalayan Mineral Water Private Limited under IBC. Statutory auditors Doogar & Associates issued an unmodified audit opinion on both standalone and consolidated results.
The muted PAT growth of ~4.6% despite acquisitions suggests integration costs or lower organic performance. The unmodified audit opinion with no going concern issues is positive. Dividend payout of 70% indicates continued shareholder returns, though investors should monitor post-acquisition profitability.